Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service? Thank you for choosing ACROBiosystems. Would you rate our product and service?
Here come GMP Grade Cytokines!Free Sample is available! Here come GMP Grade Cytokines!Free Sample is available!
Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
DLL3 mAb - 01 | Lead | Solid Tumor | Small cell lung cancer |
Expression analysis of human DLL3 on CHO/Human DLL3 Stable Cell Line by FACS.
Cell surface staining was performed on CHO/Human DLL3 Stable Cell Line or negative control cell using anti-human DLL3 antibody followed by staining with PE anti-human IgG Fc Antibody.
Expression analysis of human DLL3 on HEK293/Human DLL3 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human DLL3 Stable Cell Line or negative control cell using anti-human DLL3 antibody followed by staining with PE anti-human IgG Fc antibody.
Bispecific T-cell Engager captured on Protein A Chip can bind Cynomolgus DLL3 (27-488), His Tag (Cat. No. DL3-C52H9) with an affinity constant of 1.02 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
89Zr-DFO-SC16.56 | 89Zr-DFO-SC16.56 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Small Cell Lung Carcinoma | Details |
AMG-119 | AMG-119 | Amgen Inc | Details | ||
HPN-328 | HPN-328 | Harpoon Therapeutics | Details | ||
QLS-31904 | QLS31904; QLS-31904 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
DLL3-CAR-NK cells Therapy(Tianjin Medical University Cancer Institute and Hospital) | DLL3-CAR-NK cells | Phase 1 Clinical | Tianjin Medical University Cancer Institute And Hospital | Small Cell Lung Carcinoma | Details |
PT-217 | PT-217 | Phase 1 Clinical | Phanes Therapeutics Inc | Small Cell Lung Carcinoma; Carcinoma, Neuroendocrine | Details |
BI-764532 | BI-764532 | Phase 1 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Small Cell Lung Carcinoma; Neoplasms | Details |
OBT620 | OBT620 | Phase 1 Clinical | Boehringer Ingelheim Gmbh, Oxford Biotherapeutics Ltd | Small Cell Lung Carcinoma | Details |
Tarlatamab | AMG-757 | Phase 2 Clinical | Amgen Inc | Small Cell Lung Carcinoma; Prostatic Neoplasms | Details |
LB-2102(Legend Biotechnology) | LB-2102 | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Small Cell Lung Carcinoma | Details |
Rovalpituzumab tesirine | SC-0002; SC0001SCX; SC16LD6.5; SC0001-SCX; P256HB60FF | Phase 1 Clinical | Stemcentrx Inc, Abbvie Inc | Solid tumours; Small Cell Lung Carcinoma; Glioblastoma; Neoplasms; Prostatic Neoplasms; Medullary thyroid cancer (MTC); Carcinoma, Neuroendocrine; Melanoma | Details |
This web search service is supported by Google Inc.